ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0852

How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis

Konstantinos Tselios1, Dafna Gladman2, Haifa Al-Sheikh3, Jiandong Su4 and Murray Urowitz1, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3King Faisal Specialist Hospital and Research Centre, Riyadh, Ar Riyad, Saudi Arabia, 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: glucocorticoids, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: SLE – Treatment Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The existing guidelines for remission induction in lupus nephritis (LN) from both the ACR and the EULAR recommend initial prednisone doses of 0.5-1mg/kg/day. However, recent observational studies reported non-inferior outcomes with significantly lower doses. The aim of this study was to compare the complete renal response rates in LN patients treated initially with £30mg/day or ³40mg/day of prednisone.

Methods: Patients with new-onset LN and standard immunosuppressive treatment with azathioprine or mycophenolate mofetil in standard doses or cyclophosphamide (Euro-lupus protocol) were included and followed for at least 12 months. Subjects were divided into low-to-medium (£30mg/day) and high prednisone groups (³40mg/day) and propensity score-matched based on global and renal disease activity. Complete renal response was defined as proteinuria < 0.5g/day and no worsening in renal function (serum creatinine £120% from baseline). Glucocorticoid-related damage was also assessed.

Results: Two hundred and thirty-six patients (118 in each group) were included. Baseline characteristics were well-balanced between groups except Black patients’ predominance in the high prednisone group (25.4% vs. 15.3%, p=0.04) and higher frequency of LN class V in the low dose group (35.6% vs. 22.9%, p=0.036), Table 1. Median prednisone doses were 45mg/day and 20mg/day for the high and low-to-medium dose groups respectively. Complete renal response rates at 12 months in the main groups and certain subgroups of patients are shown in Table 2. Complete remission rates were also higher at two [75% vs. 40.3%, p=0.0002] and three years [67.2% vs. 51.7%, p=0.144] after LN diagnosis. Patients in the high dose group received less cumulative glucocorticoids during the 2nd and 3rd year after LN diagnosis and did not accrue more glucocorticoid-related damage, Table 3.

Conclusion: Higher initial prednisone doses (median 45mg/day) achieved significantly better rates of complete renal response at 12 and 24 months in new-onset LN. Findings were similar in different patient subgroups. These patients received less cumulative glucocorticoids in the 2nd and 3rd year and did not accrue more glucocorticoid-related damage. Our findings suggest that the treatment of LN with initially high doses of prednisone leads to improved rates of renal response that, in turn, allows for faster glucocorticoid tapering compared to patients who were treated with lower doses.


Disclosure: K. Tselios, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5; H. Al-Sheikh, None; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman D, Al-Sheikh H, Su J, Urowitz M. How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/how-much-prednisone-is-enough-for-remission-induction-in-lupus-nephritis-a-propensity-score-matched-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-much-prednisone-is-enough-for-remission-induction-in-lupus-nephritis-a-propensity-score-matched-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology